U.S. market Closed. Opens in 12 hours 2 minutes

ALLO | Allogene Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue95.00K243.00K38.49MN/AN/AN/A
Cost of Revenue242.91M16.73M13.06M11.54M5.03MN/A
Gross Profit-242.82M-16.48M25.42M-11.54M-5.03MN/A
Operating Expenses314.59M335.69M294.28M258.24M202.01M192.84M
Selling, General & Admin71.67M79.31M74.11M65.26M57.47M40.98M
Research & Development242.91M256.39M220.18M192.99M144.53M151.86M
Other Operating Expenses-17.84M-1.75M-2.93M-1.14M-268.00K-21.21M
Operating Income-314.49M-335.45M-255.79M-258.24M-202.01M-192.84M
Other Expenses / Income-12.77M2.82M-1.21M8.02M17.08M-21.21M
Before Tax Income-327.26M-332.63M-257.00M-250.22M-184.93M-211.62M
Income Tax Expenses13.24M-2.82M-12.17M-16.75M-331.00K-117.00K
Net Income-327.26M-329.81M-244.84M-233.47M-184.59M-211.50M
Interest ExpensesN/A-17.11MN/AN/AN/A3.36M
Basic Shares Outstanding156.93M143.15M135.82M120.37M101.06M28.95M
Diluted Shares Outstanding156.93M143.15M135.82M120.37M101.06M28.95M
EBITDA-287.05M-335.45M-255.79M-258.24M-184.93M-208.26M
EBITDA Margin-302,155.79%-138,044.86%-664.58%0.00%0.00%0.00%
EBIT-314.02M-349.74M-257.00M-250.22M-184.93M-208.26M
EBIT Margin-330,547.37%-143,927.57%-667.74%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙